Early Complications of Radioisotope Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms—A Preliminary Study
Neuroendocrine neoplasms (NENs) constitute a heterogenous group of tumors originating from neuroendocrine cells scattered throughout the body. Peptide Receptor Radionuclide Therapy (PRRT) is a treatment of choice of unresectable metastasized progressive and well-differentiated NENs. The aim of the s...
Main Authors: | Barbara Bober, Marek Saracyn, Kornelia Zaręba, Arkadiusz Lubas, Paweł Mazurkiewicz, Ewelina Wilińska, Grzegorz Kamiński |
---|---|
Format: | Article |
Language: | English |
Published: |
MDPI AG
2022-02-01
|
Series: | Journal of Clinical Medicine |
Subjects: | |
Online Access: | https://www.mdpi.com/2077-0383/11/4/919 |
Similar Items
-
Epidemiology of Neuroendocrine Neoplasms and Results of Their Treatment with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE—A Six-Year Experience in High-Reference Polish Neuroendocrine Neoplasm Center
by: Adam Daniel Durma, et al.
Published: (2023-11-01) -
Long-Term Complications of Radioligand Therapy with Lutetium-177 and Yttrium-90 in Patients with Neuroendocrine Neoplasms
by: Marek Saracyn, et al.
Published: (2022-12-01) -
Treatment of Neuroendocrine Neoplasms with Radiolabeled Peptides—Where Are We Now
by: Mitesh Naik, et al.
Published: (2022-02-01) -
Radioligand Therapy with [<sup>177</sup>Lu]Lu-DOTA-TATE or [<sup>177</sup>Lu]Lu-DOTA-TATE and [<sup>90</sup>Y]Y-DOTA-TATE in Patients with Neuroendocrine Neoplasms of Unknown Locations, or Locations Other Than the Midgut and Pancreas as Primaries in a G1, G2 and G3 Grade
by: Adam Daniel Durma, et al.
Published: (2023-08-01) -
Intra-arterial versus standard intravenous administration of lutetium-177-DOTA-octreotate in patients with NET liver metastases: study protocol for a multicenter, randomized controlled trial (LUTIA trial)
by: Sander C. Ebbers, et al.
Published: (2020-02-01)